Sotorasib: First Approval
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Surprisingly, in 2021, after unremitting efforts, a milestone was achieved: the KRASG12C inhibitor sotorasib was approved by the FDA for a specific subgroup of patients with non-small cell lung cancer (NSCLC),10”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [10]
In the citing paper
“In recent years, two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved by the United States Food and Drug Administration (US FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), 8,9 but not in mCRC as monotherapy as to date.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R. R., & O’Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 156
Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.321 · Cited by 30
Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9003 · Cited by 24 · cited 1×
“The clinical benefit of sotorasib was also seen regardless of age (< 65 vs ≥ 65 years), ECOG PS (0 vs 1), metastatic disease (yes vs no), prior lines of therapy (1 vs ≥ 2), prior anti-PD-1/PD-L1 therapy (yes vs no), TP53 co-mutation (wild-type vs mutant), STK11 comutation (wild-type vs mutant), KEAP1 co-mutation (wild…”
BackgroundReck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1730 · Cited by 21
Saiki, A. Y., Gaida, K., Rex, K., Achanta, P., Miguel, T. S., Koppada, N., Bagal, D., Lanman, B. A., Foti, R. S., McCarter, J. D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4484 · Cited by 15
Spira, A. I., Wilson, F. H., Shapiro, G. I., Dooms, C., Fontecedro, A. C., Esaki, T., Barlési, F., Cocks, K., Trigg, A., Stevinson, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9057 · Cited by 13
Hong, D. S., Strickler, J. H., Fakih, M., Falchook, G. S., Li, B. T., Durm, G. A., Burns, T. F., Ramalingam, S. S., Goldberg, S. B., Frank, R. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps2669 · Cited by 10
Research works printed but not linked: 9
- Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.
- Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.
- Amgen. FDA grants sotorasib priority review designation for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer [media release]. 16 Feb 2021. https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.
- Cardona P Simiens M Purkis J An open-label study to evaluate the effect of omeprazole on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-009] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of single and multiple doses of rifampin on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-010] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Vuu I Simiens M Purkis J A phase I, open-label study to evaluate drug-drug interactions between metformin and sotorasib (AMG 510) in healthy subjects [abstract no. PIII-018] Clin Pharmacol Ther 2021 109 Suppl. 1 S50
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of sotorasib (AMG 510) on digoxin pharmacokinetics in healthy subjects [abstract no. PII-011] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Guardant Health. Guardant360® CDx receives FDA approval as first and only liquid biopsy companion diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C inhibitor for use in advanced non-small cell lung cancer [media release]. 28 May 2021. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx.
- QIAGEN. QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer [media release]. 28 May 2021. https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Launches-First-FDA-approved-Tissue-Companion-Diagnostic-to-Identify-the-KRAS-G12C-Mutation-in-NSCLC-Tumours-and-Expand-Precision-Medicine-Options-in-Lung-Cancer/default.aspx.
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 216
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
Wu, J., & Lin, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315056 · Cited by 199
“For the treatment of adult patients with locally advanced or metastatic NSCLC with KRAS (G12C) mutations who have undergone at least one prior systemic therapy as established by the FDA-approved test, sotorasib was given accelerated approval by the FDA in May 2021 [69].”
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Fluorine-containing drugs approved by the FDA in 2021
He, J., Li, Z., Dhawan, G., Zhang, W., Sorochinsky, A. E., Butler, G., Soloshonok, V. A., & Han, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.001 · Cited by 172
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0391 · Cited by 168
Nitriles: an attractive approach to the development of covalent inhibitors
Bonatto, V., Lameiro, R. F., Rocho, F. D. R., Lameira, J., Leitão, A., & Montanari, C. A. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00204c · Cited by 137
Chandra, G., Singh, D. V., Mahato, G. K., & Patel, S. (2023) · Chemical Papers · doi:10.1007/s11696-023-02804-5 · Cited by 131
“The majority of RAS-driven cancers are caused by mutations in the KRAS isoform and mutations occurring most frequently in solid tumors such as lung adenocarcinoma, pancreatic ductal carcinoma, and colorectal carcinoma (Blair 2021; Chen et al.”
BackgroundPLK1 inhibition-based combination therapies for cancer management
Su, S., Chhabra, G., Singh, C. K., Ndiaye, M. A., & Ahmad, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101332 · Cited by 125
“BI6727 coupled with sepantronium, an inhibitor of survivin, showed potent growth inhibition of various NSCLC cell lines [60].”
BackgroundInfluentialRecent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
“The recommended dosage is 960 mg daily for sotorasib and 600 mg twice daily for adagrasib [88,89].”
BackgroundResultInfluentialTargeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 103
Hossain, M., Habib, I., Singha, K., & Kumar, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23172 · Cited by 84
The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine
Wang, Q., Han, J., Sorochinsky, A. E., Landa, A., Butler, G., & Soloshonok, V. A. (2022) · Pharmaceuticals · doi:10.3390/ph15080999 · Cited by 75
“The US FDA approved sotorasib 4 in 2021 for the treatment of adult patients, with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and colorectal cancer, who have received at least one prior systemic therapy [51].”
BackgroundBurnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01658 · Cited by 72
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 71
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
Development of PROTAC Degrader Drugs for Cancer
Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 65
Rac1 as a therapeutic anticancer target: Promises and limitations
Bailly, C., Beignet, J., Loirand, G., & Sauzeau, V. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115180 · Cited by 61
Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 64
“A milestone study in 2021, leading to the discovery of the first KRAS-targeted therapy using sotorasib, an eclectic KRASG12C inhibitor, was approved for adult NSCLC patients carrying this variant who had previously been treated with at least one systemic therapy [96].”
BackgroundWang, N., Mei, H., Dhawan, G., Zhang, W., Han, J., & Soloshonok, V. A. (2023) · Molecules · doi:10.3390/molecules28093651 · Cited by 59
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 59
“C H3 CH3 KRAS 1 Oral Non-Small Cell Lung Cancer Decreased lymphocytes, and hemoglobin, diarrhea, increased aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase, musculoskeletal pain, decreased calcium, nausea, fatigue, hepatotoxicity, cough [168]”
BackgroundTargeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 57
New drug approvals for 2021: Synthesis and clinical applications
Yuan, S., Wang, D.-S., Liu, H., Zhang, S., Yang, W., Lv, M., Zhou, Y., Zhang, S., Song, J. H., & Liu, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114898 · Cited by 55
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Lee, A. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00922-w · Cited by 53
Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer
Cao, D., Song, Q., Li, J., Jiang, Y., Wang, Z., & Lu, S. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.26 · Cited by 53
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Chen, J., Lu, W., Chen, M., Cai, Z., Zhan, P., Liu, X., Zhu, S., Ye, M., Lv, T., Lv, J., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225036 · Cited by 51
“…patients with NSCLC-harbored KRAS mutations, 35–45% were the G12C subtype, sotorasib and adagrasib are the only target drugs approved by the FDA for the treatment of patients with KRAS G12C mutation NSCLC. 103,104 However, they could not meet the needs of all kinds of KRAS -mutant NSCLC treatment.”
BackgroundLi, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00110-3 · Cited by 49
Hess, L. M., Krein, P. M., Haldane, D. C., Han, Y., & Sireci, A. N. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100336 · Cited by 48
“Although not nationally representative, the findings in this study are highly consistent with an emerging body of evidence revealing that these gaps in testing are consistent across the broader population of patients with advanced or metastatic NSCLC.”
BackgroundInfluentialManzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 47
“Among the studies of RAS-targeted therapies, sotorasib, which acts selectively and irreversibly on KRAS-mutated glycine 12 to cysteine (G12C), is an example of a medication that promoted better responses to anti-EGFR in patients with RAS mutations, which is why it was approved by the Food and Drug Administration (FDA)…”
BackgroundEmerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 48
“AMG510 (Sotorasib) and MRTX849 (Adagrasib) were recently approved for the treatment of non-small cell lung cancer (NSCLC) carrying the KRASG12C mutation[43], indicating that KRAS is no longer considered clinically undruggable.”
BackgroundTargeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Kung, H., & Yu, J. (2023) · MedComm · doi:10.1002/mco2.216 · Cited by 46
MUTYH-associated tumor syndrome: The other face of MAP
Magrin, L., Fanale, D., Brando, C., Corsini, L. R., Randazzo, U., Piazza, M. D., Gurrera, V., Pedone, E., Russo, T. D. B., Vieni, S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02304-y · Cited by 41
“Another interesting drug for MAP patients might be sotorasib, a RAS GTPase family inhibitor which selectively and irreversibly targets the KRAS G12C mutation, recently approved by the Food and Drug Administration (FDA) for the treatment of patients with KRAS G12C-mutated nonsmall cell lung cancer [65].”
BackgroundKRAS Mutations in Squamous Cell Carcinomas of the Lung
Acker, F., Stratmann, J., Aspacher, L., Nguyen, T., Wagner, S., Serve, H. L., Wild, P. J., & Sebastian, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.788084 · Cited by 39
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 39
Hou, Y., Wang, H., Wu, J., Guo, H., & Chen, X. (2024) · Medicinal Research Reviews · doi:10.1002/med.22018 · Cited by 39
Xiao, X., Chen, B., Yao, Y.-P., Zhou, H.-J., Wang, X., Wang, N., & Chen, F. (2022) · Molecules · doi:10.3390/molecules27196583 · Cited by 36
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 36
“The label dosing of sotorasib is 960 mg once daily with multiple dose level reductions available if toxicity arises [99].”
BackgroundInfluentialTedeschi, A., Schischlik, F., Rocchetti, F., Popow, J., Ebner, F., Gerlach, D., Geyer, A., Santoro, V., Boghossian, A. S., Rees, M. G., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0386 · Cited by 36
“Accordingly, sotorasib and adagrasib have received accelerated approval because of the clinical benefit observed in pretreated patients with advanced or metastatic non–small cell lung cancer (NSCLC) harboring KRAS G12C mutations (15, 16).”
Zhang, S., Luo, Z., Wang, W.-T., Qian, L., & Liao, J. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c01761 · Cited by 35
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 34
Garcia, B. N. C., van Kempen, L. C. L. T., Kuijpers, C. C. H. J., Schuuring, E. M. D., Willems, S. M., & van der Wekken, A. J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.015 · Cited by 34
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations
Sissy, F. N. E., Wassef, M., Faucon, B., Salvan, D., Nadaud, S., Coulet, F., Adle‐Biassette, H., Soubrier, F., Bisdorff, A., & Eyries, M. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18046 · Cited by 31
Ma, Z., Zhou, M., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01441 · Cited by 31
How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Discovery
Kirkman, T., Silva, C. D. S., Tosin, M., & Dias, M. V. B. (2024) · ChemMedChem · doi:10.1002/cmdc.202400342 · Cited by 31
Afonso, A. L., Cavaleiro, C. T., Castanho, M. A. R. B., Neves, V., & Cavaco, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073117 · Cited by 30
Khan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R. E., Bannoura, S. F., Mzannar, Y., Hallak, M. N. A., Kim, S. H., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0176 · Cited by 30
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 30
Synthetic Approaches to the New Drugs Approved During 2021
McInturff, E. L., France, S. P., Leverett, C. A., Flick, A. C., Lindsey, E. A., Berritt, S., Carney, D. W., DeForest, J. C., Ding, H. X., Fink, S. J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00501 · Cited by 30
US-FDA Approved Drugs in 2020 and 2021: A Review
Passi, I., Salwan, S., & Kumar, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221208104530 · Cited by 29
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
Ganguly, A., & Yoo, E. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.011 · Cited by 28
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“Based on the results of CodeBreak 100, the FDA in May 2021 approved sotorasib for KRAS G12C -mutated NSCLC patients who have received at least one prior systemic therapy, making it the first approved targeted therapy in these patients [18, 88].”
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies
Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 29
Zhao, R., Yang, S., Xu, W., Jiang, F., Ran, P., Pan, L., Wang, J., Wang, W., Zhao, J., Wang, Y., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03498-9 · Cited by 27
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., Minna, J. D., Westover, K. D., Zeh, H. J., Kroemer, G., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq4274 · Cited by 26
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer
Thein, K. Z., Biter, A. B., Banks, K. C., Duda, A. W., Saam, J. R., Roszik, J., Jankú, F., Skoulidis, F., Heymach, J. V., Kopetz, S., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00547 · Cited by 26
“Novel KRAS inhibitors, such as AMG510 and MRTX849, were shown to be clinically active securing the recent US Food and Drug Administration approval of AMG510 in patients with KRASmutated metastatic NSCLC, boosting the need for robust genotyping for this marker in oncology practice.(7-11,26) Nevertheless, to date, there…”
BackgroundCovalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Cheke, R. S., & Kharkar, P. S. (2023) · Drug Development Research · doi:10.1002/ddr.22132 · Cited by 26
“In another study by the Cheng and team in 2022, a series of novel 4(1 H ) ‐ quinoline and urea analogs were reported as potent covalent inhibitors of KRAS G12C for KRAS ‐ mutant NSCLC (Cheng et al., 2022).”
BackgroundInfluentialFluorescent Biosensor for Measuring Ras Activity in Living Cells
Weeks, R., Zhou, X., Yuan, T. L., & Zhang, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05203 · Cited by 24
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 24
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Khan, S. U., Budamagunta, V., & Zhou, D. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.004 · Cited by 23
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit
Wang, Y., Zhang, J., Li, K., Xia, S., & Gou, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01941 · Cited by 22
A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished
Ning, W., Zhang, Y., Kocher, G. J., Dorn, P., & Peng, R. (2022) · Cancers · doi:10.3390/cancers14020390 · Cited by 22
“Similarly, in the xenograft models of the NSCLC cell line H2122 and esophageal carcinoma cell line KYSE-410, adagrasib, in combination with other EGFR inhibitors, such as afatinib, resulted in a desirable outcome [33].”
BackgroundInfluentialA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
“Its common AEs include infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, decreased phosphate, increased γ glutamyl transferase, decreased lymphocytes, and hypertension (Blair 2021a).”
BackgroundTargeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 21
Novel systemic treatment approaches for metastatic pancreatic cancer
Dorman, K., Heinemann, V., Kobold, S., von Bergwelt‐Baildon, M., & Boeck, S. H. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2037552 · Cited by 20
Hu, Q., Kanwal, F., Lyu, W., Zhang, J., Liu, X., Qin, K., & Shen, F. (2022) · ACS Sensors · doi:10.1021/acssensors.2c01776 · Cited by 20
Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?
Xiao, H., Wang, G., Zhao, M., Wen, S., Ouyang, L., & Sun, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115104 · Cited by 20
Liang, H., Zhu, Y. M., & Wu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135324 · Cited by 19
Khan, H. Y., Nagasaka, M., Aboukameel, A., Alkhalili, O. A., Uddin, M. H., Bannoura, S. F., Mzannar, Y., Azar, I. H., Beal, E. W., Tobon, M. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0251 · Cited by 19
Ramsey, J. R., Shelton, P. M. M., Heiss, T. K., Olinares, P. D. B., Vostal, L. E., Soileau, H., Grasso, M. J., Casebeer, S. W., Adaniya, S. M., Miller, M., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10581 · Cited by 19
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 19
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 19
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 20
Li, J., Li, R., Ma, L.-R., Wang, P., Xu, D., Huang, J., Li, L.-Q., Tang, L. L., Xie, Y., Leung, E. L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875330 · Cited by 19
“Alternative name Sotorasib; lumakras™ Adagrasib Molecular formula C30H30F2N6O3 C32H35ClFN7O2 Structure Key features This irreversible inhibitor locks KRASG12C in an inactive GDP-bound situation and it can bind to a special groove created by His95 This small molecule inhibitor binds to Cysteine 12 in the Switch II pock…”
BackgroundInfluentialCao, Z., Wang, Q., Neumann, H., & Beller, M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410597 · Cited by 18
Wang, Y., Lu, C., Feng, J., & Liu, R. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c02303 · Cited by 18
Wong, P. S. H., Akrami, A., Houk, B. E., Vuu, I., & James, C. A. (2022) · Bioanalysis · doi:10.4155/bio-2022-0173 · Cited by 18
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
“KRAS-Targeted Agents: Sotorasib, the first KRAS G12C inhibitor approved by the U.S. FDA for metastatic NSCLC, showed a modest ORR of only 9.7% in CRC [206].”
InfluentialThomas, Q. D., Quantin, X., Lemercier, P., CHOUAID, C., Schneider, S., Filleron, T., Remon-Masip, J., Pérol, M., Debieuvre, D., Audigier-Valette, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103473 · Cited by 17
KRAS/ABHD17C/ALOX15B Axis Promotes Pancreatic Cancer Progression via Ferroptosis Evasion
Li, M., Yu, X., Liu, Y., Ouyang, S., Wu, L., Chen, X., Yu, H. J., Chen, H., Lian, S., Li, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202504470 · Cited by 17
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
Jayan, A. P., Anandu, K. R., Madhu, K., & Nirmala, S. V. (2022) · Medical Oncology · doi:10.1007/s12032-022-01744-6 · Cited by 16
Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 17
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS
Han, J., Wzorek, A., Dhawan, G., Zhang, W., Sorochinsky, A. E., Baecker, D., Ono, T., Klika, K. D., & Soloshonok, V. A. (2025) · Ukrainian Chemistry Journal · doi:10.33609/2708-129x.91.2.2025.55-90 · Cited by 15
“For example, highly grossing drugs such as Ascimi nib (Scemblix™) 1 [57], Melflufen (Pepaxto™) 2 [58], and Krazati™ (Adagrasib) 3 [59] are all chiral (Fig.”
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf
Alhazza, A., Oyegbesan, A., Bousoik, E., & Aliabadi, H. M. (2025) · Pharmaceuticals · doi:10.3390/ph18060895 · Cited by 16
Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
Pîrlog, R., Piton, N., Lamy, A., Guisier, F., Berindan‐Neagoe, I., Sabourin, J., & Marguet, F. (2022) · Cancers · doi:10.3390/cancers14041030 · Cited by 15
“These two molecules are approved by the FDA for clinical use in KRAS G12C mutated locally advanced or metastatic NSCLC that have already received at least one line of systemic therapy [19].”
BackgroundOno, H., Yamaguchi, R., Arai, M., Togi, S., Ura, H., Niida, Y., & Shimizu, A. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16822 · Cited by 15
Loos, N. H. C., Retmana, I. A., Rijmers, J., Wang, Y., Gan, C., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115304 · Cited by 16
Chen, Z., Si, G., Ding, C., Luo, T., Xu, J., Xu, S., & Li, S. (2023) · Medical Physics · doi:10.1002/mp.16744 · Cited by 14
Shen, Y., Zhang, X., Zhang, L.-Y., Zhang, Z., Lyu, B., Lai, Q., Li, Q., Zhang, Y., Ying, J., & Song, J. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208974 · Cited by 14
Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review
Zaitouni, S. E., Laraqui, A., Boustany, Y., Benmokhtar, S., Annaz, H. E., Abi, R., Tagajdid, M. R., Kochri, S. E., Bouaiti, E. A., Amine, I. L., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251331759 · Cited by 14
Arif, S. M., Floto, R. A., & Blundell, T. L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.857000 · Cited by 13
“, 2015), sotoracib (Blair, 2021) and Asciminib (Eşkazan, 2021) (Table 1).”
BackgroundOncolytic Viral Therapy for Glioma by Recombinant Sindbis Virus
Sun, K., Shi, X., Li, L., Nie, X., Xu, L., Jia, F., & Xu, F. (2023) · Cancers · doi:10.3390/cancers15194738 · Cited by 13
“Since the FDA approved the first oncolytic virus therapy in 2015 [1], various oncolytic viruses that selectively target and kill specific cancer cells for killing have been reported, and most of these studies have focused on adenoviruses, herpesviruses, and poxviruses.”
BackgroundCurrent advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
Wu, J., Li, X., Wu, C., Wang, D., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116282 · Cited by 13
Xu, P., Zhu, L., Zhang, D., Li, Z., Ge, R., & Tian, Q. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101446 · Cited by 13
Hou, J., Hao, W., Chen, Y., Wang, Z., & Yao, W. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c00555 · Cited by 13
Dahal, U. P., Rock, B. M., Rodgers, J., Shen, X., Wang, Z., & Wahlstrom, J. L. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000798 · Cited by 13
“Drug Administration approved sotorasib for treatment of patients with locally advanced or metastatic non-small cell lung cancer with the KRAS mutation (Blair, 2021).”
Background
Metadata
- Authors
- Blair, H. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Blair, Hannah A.
- Venue
- Drugs
- Published
- 2021-08-06
- Volume
- 81
- Issue
- 13
- Pages
- 1573-1579
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8531079
- OpenAlex
- W3193019540
- Cited by
- 241
- References
- 11
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 53 · 2023: 46 · 2022: 53 · 2021: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-10-23)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- sotorasib, KRAS G12C mutation, non-small cell lung cancer, drug approval, accelerated approval, colorectal cancer, solid tumors, drug development milestones
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Piperazines, Pyridines, Pyrimidines, United States, United States Food and Drug Administration, Drug Approval, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

